Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS MONTH'S ISSUE:
March 2015

A Two-Drug Combination for Weight Loss
The new medication Contrave, which combines the opioid-receptor antagonist naltrexone (ReVia and others) with the antidepressant and smoking cessation compound bupropion (Wellbutrin, Zyban, and others), has been approved as an adjunct to diet and increased exercise for certain overweight and obese patients.

Clozapine Trumps Polypharmacy
For patients with schizophrenia, clozapine (Clozaril and others) is associated with lower costs and reduced disease-specific emergency department use.

In Brief
Brain Activity in Men and Women Differs in Response to Cigarette Smoking; Patients with Anxiety Disorders Are at Greater Risk of Hypertension than the General Population

Lack of Cataracts with Quetiapine
Despite warnings about cataracts, quetiapine (Seroquel) actually appears to have a low risk of causing cataracts.

CME Reminder
March 31, 2015 is the deadline for returning your 2014 CME posttest to earn up to 12.0 hours of category 1 credit.

Affiliated Links

The Journal of Clinical Psychiatry

The University of Arizona Health Sciences Center- Department of Psychiatry

American Academy of Child and Adolescent Psychiatry

American Association of Suicidology

American Psychiatric Association

American Society for Adolescent Psychiatry

American Society of Addiction Medicine

American Society of Clinical Psychopharmacology

Autism Society of America

Depression and Bipolar Support Alliance (DBSA)

National Alliance for Research on Schizophrenia and Depression (NARSAD)

National Alliance for the Mentally Ill

National Association of Alcoholism and Drug Abuse Counselors

National Institute of Mental Health

National Mental Health Association